Yin Dandan, Dong Dong, Li Ke, Zhang Lei, Liang Jianliang, Yang Yang, Wu Nana, Bao Yiyan, Wang Chuanqing, Hu Fupin
Clinical Microbiology Laboratory, Department of Nosocomial Infection Control, Children's Hospital of Fudan University, Shanghai, China.
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00385-17. Print 2017 Aug.
Five OXA-232 carbapenemase-producing isolates, belonging to the pandemic clone sequence type 15 (ST15), were isolated from neonates and coproduced and genes. All isolates were resistant to ertapenem (MICs of >32 μg/ml) and meropenem (MICs of 4 to 8 μg/ml) and susceptible or intermediate to imipenem (MICs of 1 to 2 μg/ml). The gene was located on a ColE-type transformable plasmid of 6,141 bp. To the best of our knowledge, this is the first report of OXA-232 carbapenemase among clinical isolates in China.
从新生儿中分离出5株产OXA-232碳青霉烯酶的菌株,它们属于流行克隆序列类型15(ST15),并且共同产生了 和 基因。所有分离株对厄他培南(最低抑菌浓度>32μg/ml)和美罗培南(最低抑菌浓度为4至8μg/ml)耐药,对亚胺培南敏感或中介(最低抑菌浓度为1至2μg/ml)。 基因位于一个6141bp的ColE型可转化质粒上。据我们所知,这是中国临床分离株中首次报道OXA-232碳青霉烯酶。